Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 9/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6839406 | 0.81 | HTR2C (0.54) | HTR6HTR2CMTNR1AMTNR1BADRB2 | |
| SCHEMBL906043 | 0.81 | HTR6 (0.43) | HTR6HTR2CMTNR1AMTNR1BMAPK1 | |
| SCHEMBL906074 | 0.81 | HTR6 (0.43) | HTR6HTR2CMTNR1AMTNR1BMAPK1 | |
| SCHEMBL6641609 | 0.81 | HTR2C (0.79) | HTR6HTR2CMTNR1AMTNR1B | |
| SCHEMBL12579952 | 0.81 | HTR2C (0.71) | HTR6HTR2CMTNR1AMTNR1BMAPK1 | |
| SCHEMBL905731 | 0.77 | HTR6 (0.38) | HTR6HTR2CMAPK1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL6647520 | 0.73 | HTR2C (0.55) | HTR6HTR2CMTNR1AMTNR1BMAPK1 | |
| Fumaric Acid SCHEMBL6642673 | 0.73 | HTR2C (0.66) | HTR6HTR2CMTNR1AMTNR1BMAPK1 | |
| Fumaric Acid SCHEMBL6642671 | 0.73 | HTR2C (0.66) | HTR6HTR2CMTNR1AMTNR1BMAPK1 | |
| SCHEMBL4048331 | 0.72 | HTR6 (0.52) | HTR6HTR2CMTNR1AMTNR1BMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| EP-1620081-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| EP-1109813-B1 | PYRROLOINDOLES, PYRIDOINDOLES AND AZEPINOINDOLES AS 5-HT2C AGONISTS | VERNALIS RES LTD (GB) | 2004-08-11 | — | — | EP | disclosed |
| US-6433175-B1 | ANTISEROTONINE AGENTS | VERNALIS RESEARCH LIMITED (GB) | 2002-08-13 | — | — | US | disclosed |
| EP-1109813-A1 | PYRROLOINDOLES, PYRIDOINDOLES AND AZEPINOINDOLES AS 5-HT2C AGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012510-A1 | PYRROLOINDOLES, PYRIDOINDOLES AND AZEPINOINDOLES AS 5-HT2C AGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | HTR6 21/4885HTR2C 1/4885MTNR1A 67/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | HTR6 21/4885HTR2C 1/4885MTNR1A 67/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | HTR6 21/4885HTR2C 1/4885MTNR1A 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.